Andexanet Alfa – High-value health care through a new reversal agent for Factor Xa Inhibitors

Earlier this month, the FDA approved a biologic agent known as Andexanet alfa (Andexxa), manufactured by Portola, indicated for the reversal of anticoagulation from factor Xa inhibitors, specifically apixaban (Eliquis) and rivaroxaban (Xarelto). This represents a major advancement in the treatment of hospitalized patients facing life-threatening bleeding. Patients can be on factor Xa inhibitors for […]